Page last updated: 2024-08-23

ethylketocyclazocine and Carcinoma, Anaplastic

ethylketocyclazocine has been researched along with Carcinoma, Anaplastic in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alexaki, VI; Castanas, E; Hatzoglou, A; Kampa, M; Papakonstanti, EA; Stournaras, C1

Other Studies

1 other study(ies) available for ethylketocyclazocine and Carcinoma, Anaplastic

ArticleYear
The opioid agonist ethylketocyclazocine reverts the rapid, non-genomic effects of membrane testosterone receptors in the human prostate LNCaP cell line.
    Experimental cell research, 2004, Apr-01, Volume: 294, Issue:2

    Topics: Actin Cytoskeleton; Analgesics, Opioid; Binding Sites; Binding, Competitive; Carcinoma; Cell Division; Cell Membrane; Ethylketocyclazocine; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Male; Opioid Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Reaction Time; Receptors, Androgen; Serum Albumin, Bovine; Signal Transduction; Testosterone; Tumor Cells, Cultured

2004